Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial
Operating System™, today announced a partnership with leading
digital health company, NuvoAir, to incorporate remote collection
of respiratory endpoints data into clinical trial designs—helping
to bypass the need for patients to visit hospital sites for lung
function testing and other respiratory assessments.
NuvoAir’s clinical trial solution enables the collection and
integration of multiple endpoints which are captured from the
comfort of patients’ homes via a suite of connected devices
(spirometer, inhaler sensor, pulse oximeter, activity tracker and
nighttime cough tracker); an integrated patient app; clinician
software; and a wrap-around clinical service. This solution
facilitates the deployment of agile (hybrid) and fully
decentralized clinical trials, unlocking many of the potential
benefits of agile trials, such as universal access for patients and
providers, accelerated enrollment, better retention rates and
increased diversity of trial enrollees.
“Strengthening our network of connected devices with NuvoAir
reinforces our Agile Clinical Trial Operating System,” said David
Coman, Chief Executive Officer, Science 37. “By introducing remote
spirometry to patients’ homes, we are significantly reducing
patient burden for respiratory trials, while continuing our
objective to open up participation beyond the geographic
limitations of brick-and-mortar sites.”
Science 37 has seen up to 21x faster patient enrollment, 28%
better patient retention, and 3x more diversity from the use of
agile and fully decentralized models versus traditional clinical
trials. In a recent study, NuvoAir reported that 73% of
participating study sites said its solution had a significant
positive impact on participants’ willingness to enroll, and over
75% reported a good or excellent impact on retention. There are
3,781 active respiratory clinical trials, with an average
enrollment of 2,556 participants, according to data from Evaluate
Pharma.
“We are delighted to partner with Science 37 to usher in new
patient-centric standards for respiratory trials, internationally,”
says Lorenzo Consoli, CEO and Founder of NuvoAir. "This
partnership will open the door for more respiratory studies to
improve the trial experience for both patients and study sites, and
enable important new treatments to reach patients sooner.”
About Science 37Science 37 Holdings, Inc.’s (Nasdaq: SNCE)
mission is to enable universal access to clinical research—making
it easier for patients and providers to participate from anywhere
and helping to accelerate the development of treatments that impact
patient lives. As a pioneer of decentralized clinical trials, the
Science 37 l Operating System (OS) supports today’s more agile
clinical research designs with its full stack, end-to-end
technology platform and centralized networks of patient
communities, telemedicine investigators, mobile nurses, remote
coordinators, provider communities, and data and devices.
Configurable to enable almost any study type, the Science 37 OS
enables up to 21x faster enrollment, 28% better retention and 3x
more diverse patient population with industry-leading workflow
orchestration, evidence generation and data harmonization. For more
information, visit https://www.science37.com.
About NuvoAirNuvoAir is a digital health company that focuses
on complex patients, initially targeting respiratory conditions.
NuvoAir offers a virtual-first clinical service solution that
delivers continuous, proactive care by combining best-in-class
remote monitoring technology with proprietary biomarkers, deep
clinical expertise, and a data-driven infrastructure. Care
coordinators and coaches from NuvoAir work in close collaboration
with both patients and the care infrastructure of risk-bearing
partners to integrate NuvoAir’s technology and data to enable
personalized care for each member. NuvoAir’s patient-centric
approach also underlies its clinical trial solution. By bringing
the trial to the patient’s home, NuvoAir can dramatically improve
their experience, reducing the burden for both patients and study
sites. More information can be found at www.nuvoair.com.
Cautionary Note Regarding Forward-Looking StatementsThis press
release contains certain forward-looking statements within the
meaning of the federal securities laws, including statements
regarding the products offered by Science 37, its sales pipeline
and the markets in which it operates. These forward-looking
statements generally are identified by the words “believe,”
“project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result”
and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) the ability to maintain the listing of Science 37’s
securities on Nasdaq, (ii) volatility in the price of Science 37’s
securities due to a variety of factors, including changes in the
competitive and highly regulated industries in which Science 37
operates, variations in performance across competitors, changes in
laws and regulations affecting Science 37’s business and changes in
its capital structure, (iii) the ability to implement business
plans, forecasts, and other expectations, and to identify and
realize additional opportunities, (iv) the risk that Science 37 may
never achieve or sustain profitability, (v) the risk that Science
37 will need to raise additional capital to execute its business
plan, which may not be available on acceptable terms or at all, and
(vi) the potential adverse effects of the ongoing global COVID-19
pandemic. The foregoing list of factors is not exhaustive. You
should carefully consider the foregoing factors and the other risks
and uncertainties described in the “Risk Factors” section of our
Annual Report on Form 10-K for the fiscal year ended December 31,
2021 filed with the U.S. Securities and Exchange Commission (the
“SEC”) on March 22, 2022 and in our other documents filed by
Science 37 from time to time with the SEC. These filings identify
and address other important risks and uncertainties that could
cause actual events and results to differ materially from those
contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and Science 37 assumes no obligation and does not intend to update
or revise these forward-looking statements, whether as a result of
new information, future events, or otherwise, except as required by
law. Science 37 does not give any assurance that Science 37 will
achieve its expectations.
MEDIA INQUIRIES:Drew BustosScience 37PR@science37.com
Meera Montan NuvoAirmeera.montan@nuvoair.com
INVESTOR RELATIONS:Caroline PaulScience 37 //
GilmartinInvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Sep 2023 to Sep 2024